Tango Therapeutics Inc
TNGXHealthcare|Biotechnology|USA
$31.06
+0.52 (+1.71%)
Tangible Book
$2.72
Upcoming Data Readouts (4)
Sep 2026
Est. completion
P1P2Non Small Cell Lung Cancer
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
NCT05887492n=126
Mar 2027
Est. completion
P1P2Non Small Cell Lung Cancer
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
NCT06810544n=191
May 2027
Est. completion
P1P2MTAP-deleted Solid Tumors
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
NCT06188702n=60
Jun 2027
Est. completion
P1P2PDAC
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
NCT06922591n=183